GBP1 overexpression has been reported to play the oncogenic role and predicts a poor prognosis in glioblastoma, breast cancer, HNSCC [6], esophageal SCC (ESCC) [25], OSCC [26], ovarian cancer [27,28], and prostate cancer [29]. This evidence concerns the gene GBP1 and prostate carcinoma.